FibroScan® Probes
Fit the patient morphology with the appropriated probe
The complete non-invasive solution for liver disease management
Powered by LSM by VCTE™, CAP™* and SSM by VCTE™ as part of an overall assessment of the liver.
The new spleen stiffness measurement (SSM by VCTE™) and the embedded ultrasound localization system enable risk stratification of patients with advanced chronic liver disease and portal hypertension.
SSM by VCTE™ is a unique, patented and validated new marker for Spleen Stiffness Measurement. 109+ peer-reviewed publications support the use of SSM by VCTE™.
LSM by VCTE™ is unique, patented and validated for Liver Stiffness Measurement1. 3,245 peer-reviewed publications support the use of LSM by VCTE™.
CAP™ is unique patented and validated for liver disease management. 822 international peer-reviewed publications support the use of CAP™.
FibroScan® 630 Expert Indications for Use
The FibroScan® Expert 630 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE™ ) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE™ at 100 Hz shear wave frequency. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided.
*CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available
with SmartExam capability.
Bibliography
1.European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
Fit the patient morphology with the appropriated probe
Enhance FibroScan® liver disease assessment with biological markers
Optimize clinical workflows with real-time secure data transmission
Enhance your FibroScan® capabilities for improved management of fatty liver patients